Latest filing published 16 Sept 2026 for RxSight, Inc., €132k. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Eric Weinberg in RxSight, Inc., where the filings describe the role as senior executive. In total, 10 filings cover trades dated from 30 July 2021 to 15 September 2026.
Market trades split into 2 purchases (€424k) and 6 sales (€2.1M). Netting one side against the other leaves €1.6M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 option exercises.
The latest filing, published on 16 September 2026, reports an option exercise of €132k in RxSight, Inc. The most recent open-market purchase was published on 6 August 2021, 1,899 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations